Merck KGaA to Acquire Rapid Micro Biosystems for $0.75 Per Share in All-Cash Deal

industry_news

Merck KGaA to Acquire Rapid Micro Biosystems for $0.75 Per Share in All-Cash Deal

Updated on Nov 17, 2026, 03:45 PM IST
Written & Edited by Ashish

Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a life sciences technology company headquartered in Lexington, Massachusetts, announced on Nov. 16, 2026, that it has signed a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire all outstanding shares of the company at a price of USD 0.75 per share in an all-cash transaction.

Rapid Micro Biosystems provides mission-critical automation solutions designed to facilitate the efficient manufacturing and fast, safe release of healthcare products. Its flagship Growth Direct system automates microbial quality control testing workflows used in pharmaceutical manufacturing operations worldwide.

Leadership Commentary

Robert Spignesi, President and CEO of Rapid Micro Biosystems, said the company has built a strong partnership with Merck KGaA, Darmstadt, Germany, over the past 18 months, centered on a shared commitment to innovation and helping customers modernize and automate quality-control workflows.

 

Spignesi stated that Rapid Micro has established the Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers. He expressed confidence that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct platform's reach and more fully serve the combined global customer base.

Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany, said quality control is essential to the reliable manufacture of medicines.

 

Carli noted that customers need reliable results faster, more efficient quality-control workflows, and robust data integrity to support regulatory compliance, and that Rapid Micro Biosystems will strengthen Merck KGaA's ability to meet those needs, building on its existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.

 

Transaction Structure and Timing

The transaction is expected to close in December 2026, subject to the successful completion of a tender offer, including satisfaction of the minimum tender condition, and other customary closing conditions. Following completion of the transaction, Rapid Micro Biosystems will become part of the Life Science business of Merck KGaA, Darmstadt, Germany.

According to the company's disclosure, the tender offer has not yet commenced. When it begins, Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc., identified as the Purchaser, will file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission, and Rapid Micro Biosystems will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. Investors and security holders are advised to read these materials when they become available because they will contain important information about the tender offer.

Once filed, these documents will be available at no charge on the SEC's website. Copies of the offer to purchase and related tender offer documents may also be obtained from Merck KGaA, Darmstadt, Germany under the Investors section of its website, while the solicitation/recommendation statement may be obtained from Rapid Micro Biosystems under the Investor Relations section of its website.

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects Around the Globe

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information.

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Advisors

Perella Weinberg Partners is serving as financial advisor to Rapid Micro Biosystems, and Goodwin Procter LLP is serving as the company's legal counsel in connection with the transaction.

About Rapid Micro Biosystems

Rapid Micro Biosystems describes itself as an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables.

 

The company's Growth Direct system automates and modernizes manual microbial quality control testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.

The Growth Direct system is designed to bring the quality control lab to the manufacturing floor, delivering faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making for customers seeking to ensure a safe and consistent supply of healthcare products.

Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

 

The company has stated that it intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and complying with its disclosure obligations under Regulation FD, and investors are encouraged to monitor the website in addition to following press releases, SEC filings, public conference calls, presentations, and webcasts.

See Every Pharmaceutical Manufacturing Project Before Your Competitors Do

Pharmaceutical manufacturing development moves fast, and the winners are those who spot opportunities first. Whether you supply equipment, EPC services, or raw materials, early visibility into planned plants, expansions, and retrofits can make the difference between winning the contract and watching it go elsewhere.

 

The Global Project Tracking (GPT) platform by Blackridge Research delivers real-time intelligence on pharmaceutical manufacturing projects across markets worldwide, giving your team a constant stream of actionable leads.

 

From feasibility-stage concepts to fully operational facilities, track the entire project lifecycle in one place:

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Book a free demo today and discover how the Global Project Tracking (GPT) platform by Blackridge Research can transform your pipeline development in pharmaceutical manufacturing worldwide.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile